Company intelligence / Profile preview

aMoon

Ra'anana, Israel

Ownership: Private
Employees: ~40
Development stage: Other

Overview

aMoon is not a drug development company, but an active global healthtech and life sciences investment fund, partnering with early and late-stage companies that address high unmet medical needs in fields such as biotechnology, medtech, diagnostics, and digital health. Its investment vehicles support both early innovation and commercial expansion for groundbreaking healthcare technologies, frequently leveraging biological medicines/antibodies and AI-enabled platforms within their portfolio companies.

Modalities: AntibodyBiologicSmall moleculeDigital healthDiagnostics
Industry: Investors

Partnerships

Portfolio companies frequently collaborate with global biopharma, medtech, academic and tech corporations (specific partners are at the portfolio company level, not at aMoon fund level)

Beyond the preview

Go deeper on aMoon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aMoon.

Explore the full profile